4MNA.F MINERVA NEUROSC. DL-0001
- Market cap
- EUR 111M
- P/E
- -
- P/B
- 2.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4MNA.F undervalued?
Graham numberThe Graham number of MINERVA NEUROSC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MINERVA NEUROSC. DL-0001 fundamental analysis
No fundamental analysis for MINERVA NEUROSC. DL-0001 yet.
MINERVA NEUROSC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MINERVA NEUROSC. DL-0001
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Full company profileMINERVA NEUROSC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MINERVA NEUROSC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -45.4M | -25.2M | -23.1M | -21.8M | -15.1M | -49.0M |
| EBITDA | - | -24.7M | -21.7M | 6.02M | -293M | -49.0M |
| Net Income | -49.9M | -32.1M | -30.0M | 1.44M | -293M | -9.59M |
| EPS | -9.35 | -6.01 | -4.29 | 0.21 | -6.78 | -0.19 |
| Balance Sheet | ||||||
| Total Assets | 77.1M | 55.1M | 56.9M | 37.1M | 98.0M | 98.3M |
| Total Liabilities | 69.1M | 75.1M | 85.4M | 62.8M | 239M | 196M |
| Shareholders' Equity | 7.98M | -20.0M | -28.5M | -25.7M | -141M | -97.5M |
| Cash & Short-term Investments | 60.8M | 36.1M | 40.9M | 21.4M | 82.3M | 20.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -24.6M | -24.6M | -14.8M | -19.6M | -13.5M | -35.9M |
| Capital Expenditure | 0.00 | 16.3K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -24.6M | -24.7M | -14.8M | -19.6M | -13.5M | -35.9M |
| Ratios | ||||||
| ROE | -625.7% | - | - | - | - | - |
| ROA | -64.7% | -58.3% | -52.7% | 3.9% | -299.5% | -9.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
MINERVA NEUROSC. DL-0001 dividends
MINERVA NEUROSC. DL-0001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:8 on Jun 21, 2022.
Who owns MINERVA NEUROSC. DL-0001
- Insiders 3.13%
- Institutions 89.62%
- Public & others 7.25%
- Shares outstanding 49.8M
- Free float 36.4M
MINERVA NEUROSC. DL-0001 company profile
- Company name
- MINERVA NEUROSC. DL-0001
- Ticker
- 4MNA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 1500 District Avenue, Burlington, MA, United States, 01803
- Phone
- 617 600 7373
- Website
- minervaneurosciences.com
About MINERVA NEUROSC. DL-0001
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
MINERVA NEUROSC. DL-0001 management
7- Dr. Remy Luthringer Ph.D.Executive Chairman, CEO & Member of Scientific Advisory Board · born 1961
- Mr. Frederick W. Ahlholm CPASenior VP, CFO & Secretary · born 1966
- Mr. Joseph ReillySenior VP & COO · born 1975
- Mr. Anthony AliquoChief Accounting Officer & Principal Accounting Officer · born 1987
- Mr. William B. BoniVice President of Investor Relations & Corporate Communications · born 1952
- Mr. James O'ConnorChief Business Officer & General Counsel · born 1974
- Prof. Michael Davidson M.D.Member of Scientific Advisory Board & Chief Medical Officer · born 1950